In 2007, Petridou et al. found that serum adiponectin was not significantly different in patients with lung cancer compared with controls, though it was significantly lower in patients with advanced-stage disease, suggesting that adiponectin could be a potential marker for lung cancer progression[3]. This evidence concerns the gene ADIPOQ and lung cancer.